Suono Bio’s ultrasound-mediated drug delivery platform shows promising outcomes in its first-in-human study, demonstrating encouraging results. This is the first clinical demonstration of the feasibility and safety of applying ultrasound in the gastrointestinal tract for the purpose of delivering drugs.
From the press release:
FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio Inc., the company revolutionizing therapeutic platforms to improve the efficacy and safety of novel medicines, has released encouraging results from the first in human clinical trial testing its SuonoCalm™ platform. This is the first clinical demonstration of the feasibility and safety of applying ultrasound in the gastrointestinal tract for the purpose of delivering drugs.
“These data are compelling for our ultrasonic platform, demonstrating that ultrasound can be locally applied in the GI tract to deliver a drug, ultra-rapidly, in a safe and tolerable manner to a patient. This sets the stage for not only this clinical program, but our additional programs, including ingestible pill formats for oral delivery of biologics including nucleic acid-based medicines,” said Scott Kellogg, CEO of Suono Bio.
SuonoCalm is a therapeutic platform for the ultra-rapid administration of a wide range of medicines, including gene therapies. This lead program is intended for the treatment of ulcerative colitis and represents Suono Bio’s lead indication, addressing a significant unmet need. The core technology is also being applied in ingestible pill formats. Suono Bio’s strategy to accelerate approval and commercialization of powered delivery of drugs with diseases such as ulcerative colitis, and type 2 diabetes, where unmet need is well-documented and potential for near-term patient impacts and health system cost reduction is greatest.
“While ultrasonic energy has been used transdermally and in other medical devices, the unknown was whether patients could tolerate ultrasonic energy in the GI tract,” said Morgan Brophy, Manager of Clinical and Regulatory Affairs of Suono Bio. “We now know, and can take these data to inform our final product designs for our planned IND for treatment of ulcerative colitis with a mesalamine product.”